385 related articles for article (PubMed ID: 23987478)
1. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
Petereit C; Zaba O; Teber I; Lüders H; Grohé C
BMC Pulm Med; 2013 Aug; 13():55. PubMed ID: 23987478
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
[TBL] [Abstract][Full Text] [Related]
3. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
4. Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH.
Menzi S; Jaramillo SD; Pfister S; Schefer H; Jehle AW
Front Endocrinol (Lausanne); 2024; 15():1382066. PubMed ID: 38803472
[TBL] [Abstract][Full Text] [Related]
5. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
Estilo A; McCormick L; Rahman M
Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
[TBL] [Abstract][Full Text] [Related]
9. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
[TBL] [Abstract][Full Text] [Related]
10. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
11. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
Humayun MA; Cranston IC
BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
[TBL] [Abstract][Full Text] [Related]
12. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.
Kai K; Tominaga N; Koitabashi K; Ichikawa D; Shibagaki Y
CEN Case Rep; 2019 May; 8(2):112-118. PubMed ID: 30637666
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of hyponatremia in cancer patients.
Castillo JJ; Vincent M; Justice E
Oncologist; 2012; 17(6):756-65. PubMed ID: 22618570
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
[TBL] [Abstract][Full Text] [Related]
17. Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Yamamoto H; Kimura K; Horikirizono H; Tamura Y; Kambayashi S; Baba K; Okuda M; Mizuno T; Igase M
J Vet Med Sci; 2023 Oct; 85(10):1047-1051. PubMed ID: 37587049
[TBL] [Abstract][Full Text] [Related]
18. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of hyponatremia: role of vaptans].
Hensen J
Internist (Berl); 2010 Dec; 51(12):1499-509. PubMed ID: 21104220
[TBL] [Abstract][Full Text] [Related]
20. Syndrome of inappropriate secretion of anti-diuretic hormone due to hypothalamic hamartoma: use of tolvaptan.
Moon RJ; Soliman M; Hoogenboom L; Gilbert RD; Bird-Lieberman G; Singh J; Bockenhauer D; Kumaran A
J Pediatr Endocrinol Metab; 2023 Sep; 36(9):895-899. PubMed ID: 37327191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]